| Table 4: | |||
|
Selected
Common Adverse Events (AEs) Due to Antiretroviral Agents
|
|||
|
Drug
Class |
Agent
|
AEs
Unique
to Agent |
AE's
Common
Across Class |
| Neucleoside and nucleotide reverse transcriptase inhibitors | Zidovudine (AZT, ZDV) | Anemia, neutropenia | Lactic
acidosis with hepatic steatosis, lipodystrophy* |
| Didanosine (ddl) | Peripheral neuropathy, panreatitis | ||
| Zalcitabine (ddC) | Peripheral neuropathy | ||
| Stavudine (d4T) | Peripheral neuropathy | ||
| Lamivudine (3TC) | |||
| Abacavir (ABC) | Hypersensitivity syndrome | ||
| Tenofovir | |||
| Non-nucleoside reverse transcriptase inhibitors | Nevirapine | Hepatitis | Rash |
| Delavirdine | |||
| Efavirenz | CNS symptoms | ||
| Protease inhibitors | Indinavir | Nephrolithiasis | Lipodystrophy*, GI intolerance, hyperglycemia, lipid abnormalities |
| Ritonavir | |||
| Nelfinavir | |||
| Saquinavir | |||
| Amprenavir | |||
| Lopinavir/Ritonavir | |||
| *The
role of various antiretroviral agents in the development of lipodystrophy
is not fully understood. Abbreviations: CNS=central nervous system; GI=gastrointestinal Adapted from DHHS Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents, February 4, 2002. |
|||
|
Copyright
2002 The Cleveland Clinic Foundation
|